CLNN Stock Forecast & Price Target

Clene is a clinical-stage pharmaceutical company with a promising drug development platform that focuses on neurodegenerative diseases. Its strong data package, including biomarker reductions and survival improvements, has led to FDA acknowledgment of their proposed dataset and potential expedited approval for their lead drug CNM-Au8 in ALS. With a strong cash runway and promising data in multiple sclerosis and other indications, Clene has significant upside potential, although risks remain due to the complexity of the targeted diseases. The recent raise and expense adjustments result in an unchanged price target of $48, driven by expected milestones and license fees.

Clene is relying on the FDA considering NfL as a surrogate endpoint for ALS, which may allow for earlier market entry, but introduces risks of relying on confirmatory evidence post-approval. The continued funding from the NIH, now through NYU, adds credibility and financial backing to their development of CNM-Au8 for ALS, and their license fees and milestones have yet to be determined, leaving uncertainty for future revenue.